Nasdaq not doing the company any favours - but still plenty of greenshoots.
Ad spend is not going to go anywhere will go up and down according to the ad market.
My concern was new business and enterprise and won a few large deals. Thats the way forward for the company in product-led. If FY23 guidance is poor like FY22 then I'll sell it and report it under a tax loss. They were even talking about impairments. Pretty much expected unless ad market substantially pivots last Qtr.
- Forums
- ASX - By Stock
- APX
- Ann: 2022 Half Year Results & FY2022 Outlook
Ann: 2022 Half Year Results & FY2022 Outlook, page-4
Featured News
Add APX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.75 |
Change
0.060(2.23%) |
Mkt cap ! $717.0M |
Open | High | Low | Value | Volume |
$2.75 | $2.84 | $2.69 | $25.98M | 9.385M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 33184 | $2.75 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 3556 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 33184 | 2.750 |
2 | 10364 | 2.740 |
4 | 275933 | 2.730 |
4 | 54276 | 2.720 |
5 | 46226 | 2.710 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 3556 | 1 |
2.770 | 31956 | 4 |
2.780 | 32220 | 4 |
2.790 | 8007 | 2 |
2.800 | 42969 | 8 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
APX (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online